Objective To determine the clinical outcomes for patients with new-onset undifferentiated arthritis (UA), not fulfilling the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) classification criteria, and the clinical and imaging predictors of disease progression in these patients. Methods A prospective observational study was conducted in treatment-naïve UA patients. Baseline ultrasound involved semiquantitative assessment of grey scale (GS) synovitis and power Doppler activity (PD) at 26 joints. Outcomes were fulfilment of 2010 RA criteria (joint involvement determined clinically) and initiation of methotrexate over 12 months. Cox proportional hazards analysis was used to investigate predictors of outcome. Results Of 60 patients, 13(22%) progressed to RA and 32(53%) ever received methotrexate. Analyses of predictors of outcome were conducted in the subgroup (n=41) of patients with complete baseline data. The presence of GS was associated with progression to RA and methotrexate use: HRs (95% CI) were 1.25(1.07 to 1.45) and 1.16(1.02 to 1.32), respectively, for the number of joints with GS≥ grade 2 after adjustment for swollen joints. PD was not predictive in the low levels at which it was observed. Progression to RA was also associated with fulfilment of the 2010 criteria using ultrasound synovitis for enumerating joint involvement, higher baseline disability and radiographic erosion. Conclusions This is the first report of ultrasound findings in early UA (defined by presence of clinical synovitis and non-fulfilment of 2010 RA criteria). A significant proportion of patients with UA progressed to RA and/or required methotrexate. GS synovitis was predictive of disease progression.
Objective.: The Tight Control of inflammation in Psoriatic arthritis (TICOPA; isrctn.com: ISRCTN30147736) trial compared standard care (StdC) and tight control (TC) in early psoriatic arthritis (PsA), demonstrating better outcomes for TC. This substudy evaluated the performance metrics of modern imaging outcomes and compared them to the clinical data.Methods.: Non-contrast 0.2T magnetic resonance imaging (MRI; single hand) was assessed using the Outcomes in Rheumatology (OMERACT) PsA MRI Scoring System (PsAMRIS) with an additional global inflammation score. Ultrasound (US; same hand) was scored for greyscale, power Doppler, and erosions at the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints and scores summated.Results.: Seventy-eight patients had paired (baseline and 48 weeks) US data and 61 paired MRI data; 50 had matched clinical, MR, and US data. Significant within-group changes were seen for the inflammatory PsAMRIS components at MCP level: MRI global inflammation [median difference (range), standardized response mean (SRM)]: 3.25 (−5.0 to 12.0), 0.68; 1.0 (−4.5 to 17.5), 0.45 for TC and StdC, respectively. Similar within-group differences were obtained for US: 1.0 (−13.0 to 23.0), 0.45; 3.0 (−6.0 to 21.0), 0.77 for TC and StdC, respectively. No differences were seen between treatment groups. Significant correlations were found between baseline and change MRI and US scores. A significant correlation was found between baseline PsA disease activity scores and MRI global inflammation scores (Spearman ρ for MCP, PIP: 0.46, 0.63, respectively). No differences in erosion progression were observed.Conclusion.: The PsAMRIS and US inflammation scores demonstrated good responsiveness. No between-group differences were demonstrated, but this substudy was likely underpowered to determine differences between the 2 treatment strategies.
Objectives: To evaluate the performance of non-invasive screening tools in identifying metabolic dysfunction-associated steatotic liver disease (MASLD) causing clinically significant liver disease (CSLD) in PsA patients at high risk for liver disease, and to identify factors associated with CSLD. Methods: A single-centre, cross-sectional study of PsA patients referred for liver assessment due to suspected CSLD secondary to MASLD was conducted. Fibrosis-4 (FIB-4), Enhanced Liver Fibrosis (ELF) and BARD (BMI, aspartate aminotransferase/alanine transaminase ratio and Diabetes) scores were calculated using routine laboratory and clinical data. Liver imaging was performed as clinically indicated, including FibroScan in most patients. CSLD was defined as liver stiffness measurement (LSM) >10 kPa on FibroScan and/or US and/or biopsy showing steatosis/fibrosis/cirrhosis secondary to MASLD. Univariable and multivariable analyses identified variables independently associated with CSLD. Results: Eighty-nine PsA patients were included (median age 51.0 years; 57.3% male). Cardiometabolic comorbidities were common: 96.6% had one or more metabolic risk factor and 69.7% were obese. CSLD was identified in 55/89 patients (61.8%). In univariable analyses, hypertriglyceridaemia, hypertension, statin use, BMI >30 kg/m2, higher ELF and FIB-4 scores, and elevated LSM were significantly associated with CSLD. In multivariable regression, hypertension, BMI >30 kg/m2 and FIB-4 ≥1.3 remained independently associated. FIB-4 ≥1.3 demonstrated sensitivity of 47.8%, specificity of 77.2%, positive predictive value of 6.1% and negative predictive value of 98.0%. MTX exposure was not associated with CSLD. Conclusions: CSLD is common in high-risk PsA patients and strongly associated with metabolic risk factors. FIB-4 ≥1.3 had high negative predictive value, supporting its use as a first-line screening tool. Routine MASLD screening using a pathway incorporating FIB-4 followed by FibroScan may inform safer prescribing and improve outcomes.
Introduction: The role of MRI of the spine/sacroiliac joints to aid the diagnosis of axial spondyloarthritis (axSpA) is well established. Limited data, however, exist on the use of MRI to assess disease activity, resulting in current Assessment of SpondyloArthritis International Society (ASAS)/European Alliance of Associations for Rheumatology (EULAR) guidelines not recommending the use of MRI for this purpose. We aimed to assess the current use of MRI to assess disease activity and its impact on clinical decision making. Methods: As part of a service evaluation, we identified patients with a prior diagnosis of axSpA, who had an MRI of the spine/sacroiliac joints requested between May 2020 and December 2023 at The Leeds Teaching Hospitals Trust (Leeds) and Northwick Park Hospital (London). Clinical and demographic data were extracted from the medical notes. Data on MRI findings were extracted from the radiologist’s report. Results: Overall, 346 scans were performed in 335 patients. 301 patients had axSpA (170 radiographic axSpA, 131 non-radiographic axSpA) and 31 axial psoriatic arthritis. Patients were predominantly male (60.0%) and HLA-B27 positive (60.6%). 140/172 (80.1%) of patients had evidence of inflammation on a pre-treatment MRI scan. 224 scans (64.7%) were performed in patients on biologic/targeted synthetic disease-modifying antirheumatic drugs. Of the 346 MRIs performed during the audit period, 179 (54.7%) had evidence of active inflammation and those with active inflammation were more likely to have their treatment escalated (59.3% vs 23.2%). Conclusions: MRI is of utility in assessing disease activity with results of MRI scans directly influencing treatment decision making at the bedside. Further research exploring the relationship between MRI findings and clinical outcomes is warranted.